Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression
March 15, 2025
Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025
Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International Congress in Prague, Czech Republic.
Skyhawk Receives Australian Regulatory Approval to Extend SKY-0515 Treatment Duration in Phase 1 Huntington's Disease Patient Trial
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Huntington's Disease
Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting
SKY-1214 demonstrates impressive synergistic anti-cancer activity in vivo and in vitro in combination with multiple commonly used and emerging agents for the treatment of relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma
Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
SKY-1214, an IND-ready first-in-class FANCL/FANCI RNA splicing modulator, demonstrates tumor growth inhibition and regression to undetectable levels in NHL and difficult-to-treat MM xenograft mouse models
Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
SKY-1214, a first-in-class FANCL/FANCI RNA splicing modulator, demonstrated broad anti-cancer activity in multiple cancers, including difficult to treat multiple myeloma and non-Hodgkin's lymphoma
